-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, K5f5BxgtwvxPDA5i8r2Zp685f1HFDDYu+fnPXLpZAKbrSnP4kkqFT6ypeuk6bwMB wdhY3z4TjOSYEBCUIJQgaQ== 0000950133-03-001904.txt : 20030515 0000950133-03-001904.hdr.sgml : 20030515 20030515163817 ACCESSION NUMBER: 0000950133-03-001904 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20030515 ITEM INFORMATION: Financial statements and exhibits ITEM INFORMATION: Regulation FD Disclosure FILED AS OF DATE: 20030515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GUILFORD PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000918066 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 521841960 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-23736 FILM NUMBER: 03705409 BUSINESS ADDRESS: STREET 1: 6611 TRIBUTARY ST CITY: BALTIMORE STATE: MD ZIP: 21224 BUSINESS PHONE: 4106316300 8-K 1 w86690e8vk.htm FORM 8-K e8vk
 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Current Report Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 15, 2003

GUILFORD PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter)
         
Delaware   0-23736   52-1841960
 
 
(State or other jurisdiction of
incorporation or organization)		   (Commission File Number)   (I.R.S. Employer
Identification No.)
     
6611 Tributary Street
Baltimore, Maryland
(Address of principal executive offices)		   21224
(Zip Code)

Registrant’s telephone number, including area code: (410) 631-6300

(Former name or former address, if changed since last report)

Exhibit Index is on page 4.

 

 

INFORMATION TO BE INCLUDED IN THE REPORT

Item 7.       Financial Statements, Pro Forma Financial Information and Exhibits.
     
  (c) Exhibits  
 
  99.1 Written Statement of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. § 1350)

Item 9.       Regulation FD Disclosure.

                    In connection with the Quarterly Report of Guilford Pharmaceuticals Inc. (the “Company”) on Form 10-Q for the quarterly period ended March 31, 2003 as filed with the Securities and Exchange Commission on the date hereof, the Company filed with the Securities and Exchange Commission as correspondence the certificate required under 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002.

                     A copy of this certificate is attached hereto as Exhibit 99.1.

 

 

SIGNATURES

                  Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

       
    GUILFORD PHARMACEUTICALS INC.
 
Dated: May 15, 2003 By: /s/ Andrew R. Jordan
Andrew R. Jordan
Executive Vice President, Chief Financial
Officer, and Treasurer (Principal
Financial Officer and Principal
Accounting Officer)

 

 

INDEX TO EXHIBITS
         
Exhibit
Number		  
Exhibit Description 		 
Page
 
 
 
99.1   Written Statement of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350)   5

  EX-99.1 3 w86690exv99w1.htm EXHIBIT 99.1 exv99w1

 

Exhibit 99.1

Written Statement of Chief Executive Officer and Chief Financial Officer
Pursuant to Section 906
of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350)

     The undersigned, the Chief Executive Officer and the Chief Financial Officer of Guilford Pharmaceuticals Inc. (the “Company”), each hereby certifies that, to his knowledge on the date hereof:

  (a)   the Quarterly Report on Form 10-Q of the Company for the quarterly period ended March 31, 2003 filed on the date hereof with the Securities and Exchange Commission (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
  (b)   information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

     
          /s/ Craig R. Smith, M.D.
Craig R. Smith, M.D.
Chief Executive Officer
May 15, 2003		  
 
          /s/ Andrew R. Jordan
Andrew R. Jordan
Chief Financial Officer
May 15, 2003		  

  -----END PRIVACY-ENHANCED MESSAGE-----